NYSE: PHGE - BiomX Inc.

Yield per half year: -78.82%
Sector: Healthcare

Share chart BiomX Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials.

more details
The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0224
EV/EBITDA 0.7273
IPO date 2019-03-13
ISIN US09090D1037
Industry Biotechnology
P/BV 0.6483
P/S -41.66
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка -0.000134
Сайт https://www.biomx.com
Цена ао 0.3357
Число акций ао 0.05133 млрд
Change price per day: +16.67% (0.6389)
Change price per week: +20.23% (0.62)
Change price per month: +23.99% (0.6012)
Change price per 3 month: -29.35% (1.055)
Change price per half year: -78.82% (3.52)
Change price per year: +166.21% (0.28)
Change price per 3 year: -49.29% (1.47)
Change price per 5 year: -90.91% (8.2)
Change price per 10 year: 0% (0.7454)
Change price per year to date: +35.53% (0.55)
All parameters

Underestimation

Title Value Grade
P/S -41.98 0
P/BV 4.86 3
P/E 0 0
EV/EBITDA -0.5302 0
Total: 2.88

Efficiency

Title Value Grade
ROA, % -45 0
ROE, % -849.37 0
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.442 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 166.42 10
Yield Ebitda, % 1.85 1
Yield EPS, % 51.28 7
Total: 5
More

Institutions Volume Share, %
Orbimed Advisors LLC. 4517589 8.18
Johnson & Johnson 2133402 3.86
8vc Gp I, LLC 1086191 1.97
Renaissance Technologies, LLC 110294 0.2
MMCAP International, Inc. SPC 96805 0.18
Bridgeway Capital Management, Inc. 49500 0.09
Citadel Advisors Llc 33582 0.06
Walleye Capital LLC 21056 0.04
XTX Topco Ltd 14531 0.03
Susquehanna International Group, LLP 10908 0.02



Head Job title Payment Year of birth
Mr. Jonathan Eitan Solomon MBA CEO & Director 714.37k 1977 (48 years)
Ms. Marina Wolfson CPA CFO & Secretary 337.51k 1984 (41 year)
Dr. Merav Bassan Ph.D. Chief Development Officer 437.71k 1966 (59 years)
Prof. Rotem Sorek Ph.D. Scientific Founder N/A
Dr. Eran Elinav M.D., Ph.D. Scientific Founder N/A
Dr. Timothy K. Lu M.D., Ph.D. Scientific Founder N/A 1981 (44 years)
Ms. Inbal Benjamini-Elran C.H.R.O N/A
Mr. Assaf Oron Chief Business Officer 352.04k 1974 (51 year)

Address: Israel, Ness Ziona, 22 Einstein Street - open in Google maps, open in Yandex maps
Website: https://www.biomx.com